BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 23352769)

  • 1. An ERcentric view of Parkinson's disease.
    Mercado G; Valdés P; Hetz C
    Trends Mol Med; 2013 Mar; 19(3):165-75. PubMed ID: 23352769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ER stress and Parkinson's disease: Pathological inputs that converge into the secretory pathway.
    Mercado G; Castillo V; Soto P; Sidhu A
    Brain Res; 2016 Oct; 1648(Pt B):626-632. PubMed ID: 27103567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
    Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
    Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Galvin JE
    Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondria, calcium, and endoplasmic reticulum stress in Parkinson's disease.
    Calì T; Ottolini D; Brini M
    Biofactors; 2011; 37(3):228-40. PubMed ID: 21674642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease.
    Cóppola-Segovia V; Cavarsan C; Maia FG; Ferraz AC; Nakao LS; Lima MM; Zanata SM
    Mol Neurobiol; 2017 Oct; 54(8):5798-5806. PubMed ID: 27660269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
    Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
    J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of endoplasmic reticulum stress in Parkinson's disease.
    Tsujii S; Ishisaka M; Hara H
    Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
    Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
    Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pathological mechanisms of Parkinson's disease].
    Matsui H; Takahashi R
    Brain Nerve; 2009 Apr; 61(4):441-6. PubMed ID: 19378814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. α-Synuclein-mediated inhibition of ATF6 processing into COPII vesicles disrupts UPR signaling in Parkinson's disease.
    Credle JJ; Forcelli PA; Delannoy M; Oaks AW; Permaul E; Berry DL; Duka V; Wills J; Sidhu A
    Neurobiol Dis; 2015 Apr; 76():112-125. PubMed ID: 25725420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine D2 receptor knockout mice develop features of Parkinson disease.
    Tinsley RB; Bye CR; Parish CL; Tziotis-Vais A; George S; Culvenor JG; Li QX; Masters CL; Finkelstein DI; Horne MK
    Ann Neurol; 2009 Oct; 66(4):472-84. PubMed ID: 19847912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. α-Synuclein in Parkinson's disease: pathogenic function and translation into animal models.
    Eschbach J; Danzer KM
    Neurodegener Dis; 2014; 14(1):1-17. PubMed ID: 24080741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
    Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
    Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
    Neuroscience; 2012 Feb; 203():170-9. PubMed ID: 22198020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the unfolded protein response in Parkinson's disease.
    Hoozemans JJ; van Haastert ES; Eikelenboom P; de Vos RA; Rozemuller JM; Scheper W
    Biochem Biophys Res Commun; 2007 Mar; 354(3):707-11. PubMed ID: 17254549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoplasmic reticulum and mitochondria interplay mediates apoptotic cell death: relevance to Parkinson's disease.
    Arduíno DM; Esteves AR; Cardoso SM; Oliveira CR
    Neurochem Int; 2009 Sep; 55(5):341-8. PubMed ID: 19375464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the unfolded protein response is an early event in Alzheimer's and Parkinson's disease.
    Hoozemans JJ; van Haastert ES; Nijholt DA; Rozemuller AJ; Scheper W
    Neurodegener Dis; 2012; 10(1-4):212-5. PubMed ID: 22302012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.